Ascendis Pharma AS
A71
Company Profile
Business description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Contact
Tuborg Boulevard 12
HellerupDK-2900
DNKT: +45 70222244
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,017
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.20 | 75.80 | -0.83% |
| CAC 40 | 8,059.58 | 50.21 | -0.62% |
| DAX 40 | 23,941.37 | 191.04 | -0.79% |
| Dow JONES (US) | 47,200.15 | 136.53 | -0.29% |
| FTSE 100 | 9,693.64 | 7.73 | -0.08% |
| HKSE | 25,952.40 | 205.96 | -0.79% |
| NASDAQ | 23,636.56 | 198.16 | -0.83% |
| Nikkei 225 | 51,497.20 | 914.14 | -1.74% |
| NZX 50 Index | 13,605.96 | 49.66 | 0.37% |
| S&P 500 | 6,811.72 | 40.25 | -0.59% |
| S&P/ASX 200 | 8,813.70 | 69.00 | -0.78% |
| SSE Composite Index | 3,960.19 | 16.33 | -0.41% |